Anixa Biosciences (ANIX) Capital Expenditures (2011 - 2020)

Anixa Biosciences' (ANIX) quarterly Capital Expenditures came in at $1.0 in Q2 2020, down 99.99% on a QoQ basis from $15790.0 in Q1 2020.

Anixa Biosciences (ANIX) Capital Expenditures (2011 - 2020) Analysis & Trends

Anixa Biosciences (ANIX) has 8 years of Capital Expenditures data on file, last reported at $1.0 in Q2 2020.

Quarterly Capital Expenditures changed N/A year-over-year to $1.0 in Q2 2020, while the trailing twelve-month figure through Oct 2020 was $15791.0 (down 40.62% YoY) and the FY2020 annual result came in at $15791.0, down 91.0% from the prior year.
Capital Expenditures slipped to $1.0 in Q2 2020, from $15790.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $106012.0 in Q1 2016 to a low of $1.0 in Q2 2020.
A 4-year average of $17761.8 and a median of $9295.0 in 2018 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2017 — Capital Expenditures slumped 86.68% — and 2018, when it jumped 625.04%.
Tracing ANIX's Capital Expenditures over 4 years: stood at $1871.0 in 2016, then jumped by 611.01% to $13303.0 in 2017, then tumbled by 50.76% to $6551.0 in 2018, then sank by 99.98% to $1.0 in 2020.
The last three Capital Expenditures figures came in at $1.0 (Q2 2020), $15790.0 (Q1 2020), and $6551.0 (Q4 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	140.52 Bn	132.67 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.54 Bn	78.55 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.31 Bn	60.13 Bn	1.37 Bn	-
4	Moderna	61.77 Bn	56.64 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.26 Bn	37.16 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.19 Bn	27.88 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.71 Bn	10.31 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	251.02 Mn
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-	-

Download Data